What PlenOptika does

PlenOptika, Inc. is a privately held medical device company headquartered in Cambridge, Massachusetts, founded in 2012 out of the Madrid–MIT M+Visión Consortium. The company designs, manufactures, and distributes the QuickSee Free and QuickSee Free Pro handheld autorefractors, devices that apply Hartmann-Shack wavefront aberrometry — the same optical technology used in LASIK planning — to a sub-750 gram, calibration-free, battery-powered form factor capable of clinical-quality autorefraction and, in the Pro variant, simultaneous keratometry. Measurement acquisition takes approximately 10 seconds in standard mode or 5 seconds in screening mode, with open-view optics reducing accommodation artifact without requiring cycloplegia, and accuracy validated at 70–75% of patients within ±0.25D and 80–90% within ±0.5D of subjective refraction across 25+ IRB-based studies.

The company's commercial offering combines the hardware device with the free QuickSee Free Companion App (Android, Windows, macOS) that supports patient records, DICOM export, Bluetooth printer output, firmware updates, printable visual acuity simulations, and — on the Pro — wavefront maps, Zernike coefficients, and parameter-level screening breakdowns versus binary pass/refer outputs. Revenue is generated through one-time hardware capital purchases distributed via direct enterprise field sales, inside sales for mid-market practices, international distributors, and NGO/government procurement channels, with pricing held behind a request-quote model and a trial-before-buy program. Devices are FDA Class I 510(k)-exempt, CE Class IIa, MDR compliant, and UKCA certified, supporting deployment across the US, EU, UK, and 45+ additional countries through relationships with institutional customers including Aravind Eye Care System, Two Billion Eyes Foundation, Sarva Mangal Family Trust, Sightsavers, VOSH, Allegheny Health Network, and Luxottica. The company additionally operates a space health research track, with QuickSee Free Pro selected for the September 2024 Polaris Dawn mission in collaboration with TRISH and SpaceX.

Name

PlenOptika

Legal name

PlenOptika, Inc.

Website

https://plenoptika.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

PlenOptika designs and sells the QuickSee Free and QuickSee Free Pro handheld wavefront aberrometry autorefractors, serving optometrists, ophthalmologists, optical retailers, NGOs, and government vision health programs across 45+ countries with a portable, clinical-grade refraction device.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)

akta.pro primary industry

Refractive Diagnostics & Biometry (Autorefractors, Keratometers, Topography/Tomography, A-Scan/Optical Biometry) (HLAHAJAA)

Keywords

• Handheld autorefraction
• Wavefront aberrometry devices
• Ophthalmic medical devices
• Vision care technology
• Refractive error screening

Headquarters

HQ city

Allston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Handheld Autorefractor Device Sales: QuickSee Free and QuickSee Free Pro are sold as handheld autorefractor/keratometer devices. QuickSee Free Pro includes simultaneous AR and keratometry capability. Devices are FDA Class I 510(k)-exempt, CE marked Class IIa, MDR compliant, and UKCA certified. One-time capital purchase with no recurring consumable costs beyond standard maintenance.
2. Companion App Software: The QuickSee Free Companion App is provided at no cost to device owners. Provides data management, firmware updates, and enhanced clinical analytics. Free software upgrades provide new functionality, maintaining device value over time.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

PlenOptika designs, manufactures, and sells the QuickSee Free and QuickSee Free Pro handheld wavefront aberrometry-based autorefractors that deliver clinical-grade refractive error measurements in a portable, calibration-free form factor. The devices target vision professionals, optical retailers, NGOs, and government health programs for use in exam rooms, optical shops, mobile clinics, and community health missions.

Differentiator

Problem solved

Functional benefit

Brands

• QuickSee Free: Handheld wavefront aberrometry-based autorefractor for vision professionals, NGOs, and governments. FDA Class I 510(k)-exempt medical device.
• QuickSee Free Pro
• QuickSee Free Companion App
• Wavefront Refraction Engine

Products and services

• QuickSee Free Handheld wavefront aberrometry-based autorefractor for vision professionals, optical retailers, NGOs, and governments. Provides clinical-grade refractive error measurements in approximately 10 seconds, weighs under 750 grams, operates without calibration in any lighting condition, and runs on battery for 6+ hours. FDA Class I 510(k)-exempt, CE marked Class IIa, MDR compliant, and UKCA certified.
• QuickSee Free Pro Enhanced version of QuickSee Free with keratometry capability, designed for optometric and ophthalmological practices. Provides simultaneous autorefraction and keratometry, displays Zernike coefficients, wavefront maps, and spot diagrams, and detects higher-order aberrations (coma, spherical aberration) beyond what traditional autorefractors capture.
• QuickSee Free Companion App Free companion software for Android, Windows, and macOS that connects to QuickSee Free devices via Bluetooth. Enables patient record management, clinical data download, device settings customization, firmware updates, DICOM export, Bluetooth printing, and printable exam reports including visual acuity simulations.

Quantifiable outcome

• 70-75% of patients within ±0.25D of subjective refraction; 80-90% within ±0.5D
• +4 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature7 records

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

• Polaris Dawn Mission / SpaceXflagshipStrategic or Co-development Partner · 10 September 2024QuickSee Free Pro selected and used aboard the Polaris Dawn mission (September 2024), the farthest human mission from Earth since Apollo. Astronauts used the device to measure vision changes and study Spaceflight Associated Neuro-Ocular Syndrome (SANS) in microgravity.
• Translational Research Institute for Space Health (TRISH)flagshipStrategic or Co-development PartnerCollaboration with NASA's TRISH program for space health research. QuickSee used for pre- and post-flight vision testing with ISS astronauts. QuickSee Free Pro selected for Polaris Dawn mission to study Spaceflight Associated Neuro-Ocular Syndrome (SANS). Technology selected for its compact form, ease of use, and clinical accuracy for research applications.
• New England College of OptometrycoreStrategic or Co-development PartnerCollaboration with New England College of Optometry for clinical research, education, and understanding evolving demands of the optometry profession. Includes advisory board participation from NECO faculty.
• International Agency for the Prevention of Blindness (IAPB)coreStrategic or Co-development PartnerPlenOptika collaborates with IAPB to drive global policy innovation in eye health. QuickSee listed on IAPB Standard List of recommended eye health technology. IAPB Eye Health Technology Guide references PlenOptika technology.
• Aravind Eye Care SystemcoreStrategic or Co-development PartnerPartnership with Aravind Eye Hospital in India for clinical validation and field testing. Aravind has used QuickSee technology extensively in their mission-driven eye care programs. CEO Thulasiraj Ravilla has provided testimonials on device value.
• Massachusetts Institute of Technology (MIT)coreStrategic or Co-development PartnerPlenOptika technology was invented at MIT where first prototypes were designed. Strong ongoing R&D relationships with MIT. Co-Founder Nicholas Durr is Associate Professor at MIT. Formed from Madrid-MIT M+Visión Consortium research fellowship program.
• Sarva Mangal Family TrustcoreStrategic or Co-development PartnerSarva Mangal Family Trust is a major customer and advocate, using QuickSee technology in initiatives across India, Africa, and Southern California working toward reaching 10 million patients. Rohit Gupta from Future Communities Capital serves on board, representing this relationship.
• Two Billion Eyes FoundationcoreStrategic or Co-development PartnerTwo Billion Eyes Foundation uses QuickSee technology in mission-driven vision programs globally. Founder Bijan Azami has provided testimonial on device value.
• LuxotticaminorOthersLuxottica listed among 'Trusted by' customers/partners on PlenOptika website, indicating commercial relationship or customer engagement.
• SightsaversminorOthersSightsavers listed among 'Trusted by' customers/partners on PlenOptika website, indicating partnership for global vision care programs.
• VOSH (Volunteer Optometric Services to Humanity)minorOthersVOSH International listed among 'Trusted by' customers/partners on PlenOptika website, indicating partnership for mission-driven vision care.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/plenoptika
• Facebookfacebook.com/plenoptika
• LinkedInlinkedin.com/company/plenoptika

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PlenOptika